{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:47:02Z","timestamp":1762300022330,"version":"build-2065373602"},"reference-count":29,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>The safety profile and effectiveness of existing anti-HER2-targeted therapies have not been evaluated in patients with breast cancer and visceral crisis. We report the case of a 26-year-old woman who was diagnosed with advanced HER2-positive breast cancer and initially treated with curative intent therapy in a neoadjuvant setting, using Trastuzumab and Pertuzumab in combination with Docetaxel; her cancer recurred two years later, with liver metastases and pulmonary lymphangitic carcinomatosis, causing visceral crisis. Furthermore, the patient\u2019s clinical status worsened when she developed respiratory failure, hepatomegaly and a severe hepatocytolysis. Since the patient was free of disease more than six months, we started with Paclitaxel half dose because of the hepatic dysfunction, and we gradually reintroduced Trastuzumab and then Pertuzumab. In the meantime, the patient changed her lifestyle by increasing her consumption of fresh fruits and vegetables and fiber and reducing her intake of processed meat, dairy and sugar. As a result, the patient showed a significant improvement in her respiratory symptoms and liver tests in less than two months. Imaging reevaluation showed partial remission of liver metastases and pulmonary lymphangitic carcinomatosis. She underwent seven months of dual anti-HER2 blockade before relapsing cerebrally. Our results suggest that the sequential combination therapy with Trastuzumab, Pertuzumab and Paclitaxel presented in this study, associated with a healthy lifestyle, may be a good management for recurrent HER2-positive breast cancer with pulmonary visceral crisis and severe liver dysfunction.<\/jats:p>","DOI":"10.3390\/curroncol29030154","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T11:46:47Z","timestamp":1646912807000},"page":"1890-1901","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Management of HER2-Positive Breast Cancer for a Young Patient with Visceral Crisis\u2014The Adjuvant Role of Lifestyle Changes"],"prefix":"10.3390","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2948-0365","authenticated-orcid":false,"given":"Larisa Maria","family":"Badau","sequence":"first","affiliation":[{"name":"Department of Hygiene, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, Bd. Victor Babes No. 16, 300226 Timisoara, Romania"},{"name":"Department of Oncology\u2014ONCOHELP Hospital Timisoara, Ciprian Porumbescu Street, No. 59, 300239 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei Dorin","family":"Ciocoiu","sequence":"additional","affiliation":[{"name":"Department of Oncology\u2014ONCOHELP Hospital Timisoara, Ciprian Porumbescu Street, No. 59, 300239 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5000-5422","authenticated-orcid":false,"given":"Cristina Marinela","family":"Oprean","sequence":"additional","affiliation":[{"name":"Department of Oncology\u2014ONCOHELP Hospital Timisoara, Ciprian Porumbescu Street, No. 59, 300239 Timisoara, Romania"},{"name":"ANAPATMOL Research Center, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, Eftimie Murgu Sq., No. 2, 300041 Timisoara, Romania"},{"name":"Department of Oncology\u2014ONCOMED Outpatient Unit Timisoara, Ciprian Porumbescu Street, No. 59, 300239 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nusa Alina","family":"Segarceanu","sequence":"additional","affiliation":[{"name":"Department of Oncology\u2014ONCOHELP Hospital Timisoara, Ciprian Porumbescu Street, No. 59, 300239 Timisoara, Romania"},{"name":"Department of Oncology\u2014ONCOMED Outpatient Unit Timisoara, Ciprian Porumbescu Street, No. 59, 300239 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adelina","family":"Gheju","sequence":"additional","affiliation":[{"name":"Department of Morphopathology, \u201cVictor Babe\u015f\u201d University of Medicine and Pharmacy, Eftimie Murgu Sq., No. 2, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitha","family":"Vlaicu","sequence":"additional","affiliation":[{"name":"Department of Hygiene, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, Bd. Victor Babes No. 16, 300226 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"(2021, October 18). Number of New Cases in 2020\u2014Globocan. Available online: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/642-romania-fact-sheets.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: Final analysis of the HERceptin Adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.semcancer.2019.08.012","article-title":"Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets","volume":"60","author":"Liang","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11912-019-0802-6","article-title":"Systemic Therapy of Central Nervous System Metastases of Breast Cancer","volume":"21","author":"Leone","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_9","first-page":"7","article-title":"Lymphangitis carcinomatosa: A literature review","volume":"41","author":"Bruce","year":"1996","journal-title":"J. R. Coll. Surg. Edinb."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.cgh.2014.09.040","article-title":"Malignant Infiltration of the Liver Presenting as Acute Liver Failure","volume":"13","author":"Rich","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_11","first-page":"62","article-title":"Occult Breast Malignancy Masquerading as Acute Hepatic Failure","volume":"7","author":"Goswami","year":"2011","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_12","unstructured":"Ak, A.K., and Mantri, S.N. (2021, October 24). Lymphangitic Carcinomatosis, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560921\/."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2169\/internalmedicine.46.6363","article-title":"A Patient with Pulmonary Lymphangitic Carcinomatosis Successfully Treated with TS-1 and Cisplatin","volume":"46","author":"Kikuchi","year":"2007","journal-title":"Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1177\/030089160609200417","article-title":"Acute Liver Failure as the Initial Manifestation of Hepatic Infiltration by a Solid Tumor: Report of 5 Cases and Review of the Literature","volume":"92","author":"Alexopoulou","year":"2006","journal-title":"Tumori J."},{"key":"ref_15","first-page":"65","article-title":"Metastatic Breast Cancer Presenting as Acute Liver Failure","volume":"7","author":"Nazario","year":"2011","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_16","unstructured":"(2021, October 24). NCCN Guidelines Version 1.2022\u2014Invasive Breast Cancer. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.14740\/wjon1043w","article-title":"Visceral Crisis Means Short Survival Among Patients With Luminal A Metastatic Breast Cancer: A Retrospective Cohort Study","volume":"8","author":"Sbitti","year":"2017","journal-title":"World J. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5858\/2010-0454-RAR.1","article-title":"HER 2: Biology, Detection, and Clinical Implications","volume":"135","author":"Gutierrez","year":"2011","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_19","unstructured":"(2021, October 19). HER2-Positive Metastatic Breast Cancer: A Comprehensive Review\u2014Hematology & Oncology. Available online: https:\/\/www.hematologyandoncology.net\/archives\/january-2021\/her2-positive-metastatic-breast-cancer-a-comprehensive-review\/."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/OP.21.00172","article-title":"Current and Future Management of HER2-Positive Metastatic Breast Cancer","volume":"17","author":"Prat","year":"2021","journal-title":"JCO Oncol. Pract."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/annonc\/mdz061","article-title":"Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)","volume":"30","author":"Bachelot","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s12032-010-9536-x","article-title":"Physical activity and survival after breast cancer diagnosis: Meta-analysis of published studies","volume":"28","author":"Ibrahim","year":"2011","journal-title":"Med. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1002\/cphy.c120005","article-title":"Cancer, physical activity, and exercise","volume":"2","author":"Brown","year":"2012","journal-title":"Compr. Physiol."},{"key":"ref_24","first-page":"1091","article-title":"Long-term survival of a breast cancer patient with liver metastasis treated with trastuzumab and Paclitaxel","volume":"37","author":"Ota","year":"2010","journal-title":"Gan Kagaku Ryoho Cancer Chemother."},{"key":"ref_25","first-page":"225","article-title":"Successful treatment of trastuzumab-resistant HER2-positive breast cancer with extensive liver metastases using the combination of trastuzumab and capecitabine\u2014A case report","volume":"40","author":"Shigekawa","year":"2013","journal-title":"Gan Kagaku Ryoho Cancer Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"BMT45","DOI":"10.2217\/bmt-2020-0019","article-title":"How safe is it to administer dual anti-HER2 block with pertuzumab and trastuzumab on a patient with life-threatening liver breast cancer metastasis?","volume":"9","author":"Rossi","year":"2020","journal-title":"Breast Cancer Manag."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"bcr2013203400","DOI":"10.1136\/bcr-2013-203400","article-title":"Metastatic human epidermal growth factor 2 (HER2\/neu) amplified breast cancer with acute fulminant hepatitis responding to trastuzumab, pertuzumab and carboplatin","volume":"2014","author":"Macias","year":"2014","journal-title":"BMJ Case Rep."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Yu, Z., Sankar, S., and Huben, M. (2017). Excellent Response with Ado-Trastuzumab Emtansine in a Patient with Relapsed Metastatic Breast Cancer Presenting with Pulmonary Lymphangitic Carcinomatosis. Cureus, 9, Available online: https:\/\/www.cureus.com\/articles\/7491-excellent-response-with-ado-trastuzumab-emtansine-in-a-patient-with-relapsed-metastatic-breast-cancer-presenting-with-pulmonary-lymphangitic-carcinomatosis.","DOI":"10.7759\/cureus.1473"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/annonc\/mdu486","article-title":"Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: A retrospective, exploratory analysis in EMILIA","volume":"26","author":"Krop","year":"2015","journal-title":"Ann. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/3\/154\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:34:12Z","timestamp":1760135652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/3\/154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,10]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["curroncol29030154"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29030154","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2022,3,10]]}}}